How Drug Makers Manipulate Patents to Keep Insulin Prices High ...Middle East

Time - News
How Drug Makers Manipulate Patents to Keep Insulin Prices High
The financial burden of high insulin costs that patients and insurers face is often blamed on the Food and Drug Administration’s (FDA) regulatory framework, but a new study suggests pharmaceutical companies have also been using patenting processes to unfairly maintain high costs. In the FDA’s master list of approved medications, devices, and other therapeutics, a document known as the Orange Book, patent ownership of each item governs which companies are allowed to manufacture and sell which therapies. The FDA deals with drug approval, but patents are granted by another agency entirely, the U.S. Patent and Trademark Office (USPTO). [time-brightcove not-tgx=”true”] Though there a

Hence then, the article about how drug makers manipulate patents to keep insulin prices high was published today ( ) and is available on Time ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( How Drug Makers Manipulate Patents to Keep Insulin Prices High )

Apple Storegoogle play

Last updated :

Also on site :